Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced a conference call on May 10, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021, ending March 31, 2021. The call will provide updates on the company’s progress, particularly focusing on FT218, a sodium oxybate formulation intended for treating narcolepsy symptoms. Investors can join via dial-in or listen to a live webcast from the investor relations section of Avadel's website, with a replay available for 90 days.

Positive

• The upcoming conference call could signal effective communication and transparency with investors.
• FT218 is positioned to address significant needs in narcolepsy treatment.

Negative

• None.

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 10, 2021, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2021.

To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13719428. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

Contacts:

Investor Contacts
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com
        
Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915-2564
Email: tim@lifesciadvisors.com

Media Contact
Patrick Bursey
LifeSci Communications, LLC
Phone: (646) 970-4688
Email: pbursey@lifescicomms.com

FAQ

What is Avadel Pharmaceuticals planning to discuss in their May 10, 2021 conference call?

Avadel Pharmaceuticals will discuss its financial results for Q1 2021 and provide updates on FT218, its investigational drug for narcolepsy.

When does Avadel Pharmaceuticals' Q1 2021 conference call take place?

The conference call will take place on May 10, 2021, at 8:30 a.m. ET.

How can investors access Avadel Pharmaceuticals' May 10, 2021 conference call?

Investors can access the call by dialing (877) 407-9716 for U.S. and Canada or (201) 493-6779 internationally. A live audio webcast will also be available on Avadel's website.